Avalo Therapeutics Inc - Asset Resilience Ratio

Latest as of September 2025: 67.67%

Avalo Therapeutics Inc (AVTX) has an Asset Resilience Ratio of 67.67% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AVTX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$84.65 Million

Cash + Short-term Investments

Total Assets

$125.10 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2020)

This chart shows how Avalo Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Avalo Therapeutics Inc asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Avalo Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Avalo Therapeutics Inc total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$84.65 Million	67.67%
Total Liquid Assets	$84.65 Million	67.67%

Asset Resilience Insights

Very High Liquidity: Avalo Therapeutics Inc maintains exceptional liquid asset reserves at 67.67% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Avalo Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Avalo Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
ALK-Abelló A/S CO:ALK-B	Biotechnology	0.98%
Mirum Pharmaceuticals Inc NASDAQ:MIRM	Biotechnology	6.89%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Beijing Konruns Pharmaceutical Co Ltd SHG:603590	Biotechnology	10.55%

Annual Asset Resilience Ratio for Avalo Therapeutics Inc (2019–2020)

The table below shows the annual Asset Resilience Ratio data for Avalo Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2020-12-31	0.00%	$0.00	$43.76 Million	--
2019-12-31	21.13%	$7.63 Million	$36.11 Million	--

pp = percentage points

About Avalo Therapeutics Inc

NASDAQ:AVTX USA Biotechnology

Market Cap

$308.98 Million

Market Cap Rank

#14779 Global

#3495 in USA

Share Price

$16.69

Change (1 day)

+0.66%

52-Week Range

$10.80 - $22.87

All Time High

$20793.60